The large, phase III FIGARO-DKD trial strengthen the evidence on cardiovascular benefit (CV) of the nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone, in addition to its renal benefit, across a wide spectrum of patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).
Despite the high uptake of diabetes-related technologies, glucose control seems to remain suboptimal in young people with type 1 diabetes, with more than 60 percent failing to reach the target glycated haemoglobin (HbA1c) level, according to a recent Norway study.
Empagliflozin significantly reduces the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) vs placebo in patients with heart failure with preserved ejection fraction (HFpEF) with or without diabetes, according to results of the EMPEROR-Preserved trial presented at the European Society of Cardiology (ESC) Congress 2021.
Regular intake of saturated fatty acids (SFA) from meat could increase cardiovascular disease (CVD) risk whereas dairy sources, grains, fruits, and vegetables could be cardio-protective, suggests a study in the UK.
A landmark trial reveals sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin is the first therapy to show significant improvement in heart failure outcomes in adults with preserved ejection fraction.